WHOOP Unveils WHOOP® 5.0 and WHOOP® MG: Powerful New Devices with Breakthrough Health and Longevity Features
These innovations arrive at a pivotal moment when ailing health systems cost more and deliver less. WHOOP is advancing a new solution and a better way - one that empowers people to connect their daily decisions to performance and health outcomes that can be measured and felt. While others track surface-level trends, WHOOP delivers longevity through depth — translating the body's most vital signals into guidance that extends healthspan, not just lifespan.
'This isn't just a product launch. It's a new chapter for WHOOP and for our members,' said Will Ahmed, WHOOP Founder & CEO. 'We've taken everything we've learned over the past decade and built a platform to help our members perform and live at their peak for longer. We've held nothing back.'
Imagery of WHOOP 5.0 and WHOOP MG h ere.
NEW HEALTH AND PERFORMANCE IN-APP FEATURES:
Healthspan with WHOOP Age 1: Get insights and guidance on how your daily habits impact your long-term health with Healthspan - a powerful new way to quantify your physiological age and slow your Pace of Aging. Developed in partnership with Dr. Eric Verdin, CEO of the Buck Institute for Research on Aging, Healthspan uses nine different metrics linked to long-term health to calculate your WHOOP Age and Pace of Aging.
Heart Screener with ECG 2: Your heart, in your hands. WHOOP now includes an FDA-cleared ECG feature that allows a reading to be taken anytime, from your wrist — and shared directly with a healthcare provider. The Heart Screener detects signs of Atrial Fibrillation (Afib) 3, a leading cause of stroke, and provides Irregular Heart Rhythm Notifications 4 (IHRN) for greater peace of mind.
Blood Pressure Insights 5: A patent-pending technology that delivers daily blood pressure insights, right from your wrist. Get estimated systolic and diastolic readings, and learn about how blood pressure affects wellbeing and performance.
Women's Hormonal Insights 6: WHOOP goes beyond cycle tracking to deliver science-backed education and personalized insights on how hormonal shifts influence recovery, sleep, stress and performance. Whether you're navigating menstruation, pregnancy, or perimenopause — WHOOP adapts with you.
Sleep Performance Update: Unlock better nights and better days. The reimagined Sleep Score delivers a more accurate reflection of sleep quality, helping members recover more effectively and show up stronger each day.
WHOOP Advanced Labs 7: Join the waitlist for the next evolution in personalized health. Coming soon, WHOOP Advanced Labs will allow members to schedule blood tests and receive clinician reports that are integrated directly into the WHOOP app, creating a more comprehensive picture of your health — and giving you actionable steps to improve it.
Comprehensive Fitness Tracking: From daily steps and VO₂ Max to Muscular Strain during strength training and 145+ supported activities, members can now optimize fitness for both performance and long-term health outcomes.
HARDWARE, REIMAGINED FOR PERFORMANCE AND PRECISION:
Precision Sensors. Smaller Design. Greater Power: WHOOP 5.0 and MG pack more technology into a seven percent smaller form factor. Enhanced sensors capture data 26 times per second, while a redesigned processor delivers 10x more power efficiency — enabling richer insights without sacrificing battery life or comfort.
14+ Day Battery Life. New Wireless PowerPack 8: 14+ days per charge across WHOOP 5.0 and MG hardware. Now, members with their device alongside the new Wireless Powerpack have access to a full month of battery life.
Elevated Accessories: Complete the experience with a new line of WHOOP accessories — including the new LeatherLuxe, crafted from genuine Italian leather for our most premium look and feel yet.
24/7 Wearability: WHOOP remains the only wearable that's truly wearable — designed for 24/7 use across multiple locations on the body. Powered by WHOOP Body and AnyWear™ technology, our technical garments seamlessly integrate with your device to capture data with unmatched precision — no matter your sport, lifestyle or movement.
Medical-Grade ECG: Available exclusively on WHOOP MG, maintain peace of mind with medical-grade ECG readings you can do from the comfort of home. Simply place your thumb and index finger on the ECG-conductive clasp, and get a medical-grade reading in seconds.
CHOOSE YOUR EXPERIENCE:
To make these innovations even more accessible, WHOOP is also introducing three new membership tiers. These tiers empower WHOOP members to choose the hardware device, features and pricing that make the most sense for them:
WHOOP One: Professional-grade fitness insights at our best price at $199 per year
WHOOP Peak: Advanced health, fitness and longevity insights designed to help you perform at your peak, longer. Priced at $239 per year
WHOOP Life: The most powerful WHOOP ever, delivering medical-grade health and performance insights. Priced at $359 per year
See below for global pricing.
'WHOOP is a great tool. It's like a doctor on my wrist,' said Cristiano Ronaldo, Professional Soccer Player and WHOOP Global Ambassador and Investor. 'It allows me to monitor my behavior easily, and shows me that being consistent and prioritizing your health is worth it. I'm happy to be part of this company, and the launch of the WHOOP 5.0 and MG.'
WHOOP 5.0 and MG are available to purchase now on WHOOP.com.
Global Pricing
About WHOOP
WHOOP, the human performance company, offers a wearable health and fitness coach to help people achieve their goals. The WHOOP membership provides best-in-class wearable technology, actionable feedback, and recommendations across recovery, sleep, training, and health. WHOOP 5.0 and WHOOP MG offer groundbreaking health innovations, including cardiovascular health features; Healthspan which quantifies Pace of Aging and provides members with their WHOOP Age; and first-of-its-kind wearable Blood Pressure Insights. WHOOP is the perfect health companion for anyone looking to optimize their health and performance. Founded in 2012, WHOOP is based in Boston and has raised more than $400 million in venture capital. WHOOP is available to ship in 56 markets worldwide and the WHOOP app is available in English, French, German, Italian and Spanish (Latin America). WHOOP can be purchased on Amazon across the U.S., U.K., and Australia, as well as Best Buy (U.S.) Dick's Sporting Goods (U.S.), Flipkart (India) and Virgin Megastore (GCC), and more.
To learn more or start a one-month free trial, visit whoop.com and connect with WHOOP on Instagram, X, Facebook, LinkedIn, and YouTube.
_________________________________
1 This feature is not available for users under the age of 18.
2 This feature is not intended for users with known arrhythmias other than AFib or users under 22 years old. It is not recommended for users with a cardiac pacemaker, ICDs or other implanted electronic devices. This is a medically regulated feature and is not currently available in every region.
3 https://pubmed.ncbi.nlm.nih.gov/33516402/
4 This feature is not intended for users with known atrial fibrillation or users under 22 years old. This is a medically regulated feature and is not currently available in every region.
5 Blood Pressure Monitor is not a medical device and cannot diagnose or manage medical conditions. It does not provide medical advice. Always consult your doctor for health concerns and never delay or modify medical care based on its information.
6 Menstrual Cycle Insights should not be used for birth control or fertility tracking. The ovulatory phase indicators are estimates only. Menstrual Cycle Insights is not a medical device and cannot diagnose or manage medical conditions. It does not provide medical advice. Always consult your doctor for health concerns and never delay or modify medical care based on its information.
7 USA only at launch.
8 Wireless PowerPack is offered with Peak & Life Memberships. Wired battery pack available on One.
Expand
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
TMO Receives FDA Approval for Oncomine Dx Target Test
Thermo Fisher Scientific TMO recently received approval from the Food and Drug Administration ('FDA') for its Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients who may be candidates for HERNEXEOS (zongertinib tablets), a tyrosine kinase inhibitor (TKI). The HERNEXEOS, developed by Boehringer Ingelheim, is the first and only FDA-approved orally administered targeted therapy for adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC). The recent approval is expected to bolster Thermo Fisher's Specialty Diagnostics arm. About TMO's Oncomine Dx Target Test The Oncomine Dx Target Test checks if NSCLC tumors harbor human epidermal growth factor receptor 2 (HER2/ERBB2) tyrosine kinase domain (TKD) activating mutations. It enables multi-biomarker analysis from a single tissue sample to aid treatment decisions in as little as four days. This reduces the need for second biopsies and avoids suboptimal therapy selection in the absence of a complete biomarker report. The test is fully reimbursed by Medicare, as well as by the top 20 commercial payers in the United States. Oncomine Dx Target Test's Global Approvals The Oncomine Dx Target Test received its first approval by the FDA as an NGS CDx in 2017, followed by regulatory approvals in 20 countries for 11 biomarkers and over 20 targeted therapies. The test is reimbursed by government and commercial insurers in the United States, Europe, Japan, South Korea and Israel, covering more than 550 million lives globally. In the United States alone, it is approved for targeted therapies in NSCLC, cholangiocarcinoma (CC), astrocytoma (AC) and oligodendroglioma (OG), anaplastic thyroid cancer (ATC), medullary thyroid cancer (MTC) and thyroid cancer (TC). Industry Prospects Favor TMO According to the American Cancer Society, lung cancer is the second most common cancer in both men and women in the United States, with NSCLC accounting for about 85-90% of all lung cancer cases. Research further indicates that roughly 2-4% of NSCLC patients carry a HER2 mutation. With lung cancer cases continuing to rise, the global market for NSCLC treatments is expected to expand significantly, reaching $66.04 billion by 2032 at a CAGR of 10.3% from 2024 to 2032 (per Fortune Business Insights). Another Development by TMO Thermo Fisher recently announced the FDA approval for Oncomine Dx Express Test on the Ion Torrent Genexus Dx Integrated Sequencer as an in vitro diagnostic (IVD) assay for use as a companion diagnostic (CDx) for Dizal's ZEGFROVY (sunvozertinib) and in tumor profiling. Offerings by TMO's Competitors In the oncology space, Thermo Fisher faces competition from some prominent MedTech players. These companies are also making notable developments in their respective businesses. An expanding NGS oncology portfolio is helping Illumina ILMN drive the revolution in cancer genomics. The company's market-leading TruSight Oncology assay, TSO 500, continues to see increased utilization and broader adoption. In February, the company announced a new single-cell offering for CRISPR research with applications in oncology, immunology and drug target discovery. In 2024, the FDA approved its in vitro diagnostic (IVD) TSO Comprehensive test and its first two companion diagnostic (CDx) indications to rapidly match patients to targeted therapies. This year, Illumina is set to roll out TSO 500 v2, a new version that includes hundreds of genes across all variant classes and immuno-oncology biomarkers in a single assay from one sample, to facilitate therapy selection research. A rapidly expanding liquid biopsy and NGS-based testing portfolio is positioning Guardant Health GH as a leader in precision oncology. The company's flagship Guardant360 test has been recently enhanced with the Guardant Infinity platform, enabling a single blood draw to provide comprehensive tumor profiling, confirm the absence of actionable mutations and determine ER/PR/HER2 status. Regulatory milestones include approvals for Guardant360 CDx as a companion diagnostic in the United States, Japan and Singapore, covering multiple cancer targets such as EGFR and HER2 mutations. Its pipeline also includes the FDA-approved Shield blood test for colorectal cancer screening, offering a non-invasive alternative to colonoscopy. Exact Sciences' EXAS flagship screening product, the Cologuard test, is a non-invasive, stool-based DNA (sDNA) screening test that utilizes a multitarget approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company's precision oncology portfolio also offers the Oncotype DX Breast Recurrence Score test to identify patients who are most likely to benefit from chemotherapy, as well as those who may receive no clinical benefit from chemotherapy. Its Oncotype DX Colon Recurrence Score test is a multi-gene test for predicting recurrence risk in patients with stage II and stage III A/B colon cancer to enable an individualized approach to treatment planning. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report Illumina, Inc. (ILMN) : Free Stock Analysis Report Exact Sciences Corporation (EXAS) : Free Stock Analysis Report Guardant Health, Inc. (GH) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Epoch Times
4 hours ago
- Epoch Times
FDA Advises Americans Against ‘Mousse' Sunscreens, Warns 5 Manufacturers
Americans should 'beware' of sunscreen products in mousse form as they may not be effective, the Food and Drug Administration (FDA) said in an Aug. 12 X post, with the agency sending warning letters to five companies marketing sunscreen products. The letters were sent on Aug. 6 to Texas-based Supergoop, Pennsylvania-based Fallien Cosmeceuticals Ltd., Israel-based K & Care Organics, Sweden-based Kalani AB, and Florida-based Vacation Inc.
Yahoo
10 hours ago
- Yahoo
Radiopharm Theranostics Limited (RADX) Receives IND Approval From FDA To Initiate Phase I Therapeutic Clinical Study To Target B7H3 With Betabart (RV-01)
Radiopharm Theranostics Limited (NASDAQ:RADX) is among the 12 Best Australian Stocks to Buy Right Now. The company recently announced receiving Investigational New Drug (IND) approval from the FDA to begin a Phase 1 therapeutic clinical study to target B7H3 with Betabart (RV-01). A well-stocked pharmacy shelf full of the company's pharmaceuticals, nutraceuticals, over-the-counter medications, and health care products. The Lu-177-B7H3 monoclonal antibody is the first in class targeted radiopharmaceutical that is being developed against the 4lg type of B7H3. Radiopharm Theranostics Limited (NASDAQ:RADX) believes it has the potential to become a highly differentiated drug for treating individuals with aggressive solid tumors. The company says it is on track to initiate the first-in-human study during the fourth quarter of this calendar year. Findings from recent preclinical studies have shown that RV-01 exhibits hepatic clearance, which allows the isotope enough time to target tumors, while also potentially reducing adverse effects such as hematological toxicities. Moreover, these monoclonal antibodies are cleared by the liver, unlike peptides and small molecules. This, coupled with the shortened half-life of RV-01, makes this agent stand out compared to other monoclonal antibodies and targeted radiotherapeutics with a renal excretion pathway. Radiopharm Theranostics Limited (NASDAQ:RADX) is an Australia-based clinical-stage radiotherapeutics firm developing innovative radiopharmaceutical products for therapeutic and diagnostic applications in areas of high unmet medical need. While we acknowledge the potential of RADX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 11 Best Large Cap Defense Stocks to Buy According to Analysts and 10 Best Low Priced Defense Stocks to Buy Now. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
